Treatment Pathways and Guidance

 

National Institute for Health and Care Excellence (NICE)


Improving outcomes for people with brain and other central nervous system tumours (2006)

Brain tumours (primary) and brain metastases in adults (2018)

Neuropathology


Dataset for tumours of the central nervous system, including the pituitary gland (4th Edition) (Royal College of Pathologists:  January 2016)

Diagnosis and Treatment


Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group (The Lancet Oncology January 2018)

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group (The Lancet Oncology January 2018)

Diagnosis of Brain Tumours in Children

EANO guidelines for the diagnosis and treatment of ependymal tumors (Neuro-Oncology, November 2017)

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours (Annals of Oncology, July 2017)

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma (The Lancet Oncology, June 2017)

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas (The Lancet Oncology, June 2017)

Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) (Neuro-oncology February 2017)

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group (Annals of Oncology February 2017)

EANO guidelines for the diagnosis and treatment of meningiomas (Lancet Oncology September 2016)

Radiation Therapy for Glioblastoma: Executive Summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline (Practical Radiation Oncology July 2016)

ESTRO-ACROP guideline “target delineation of glioblastomas” (Radiotherapy Oncology, January 2016)

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group (The Lancet Oncology November 2015)

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology (The Lancet Oncology July 2015)

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma (The Lancet Oncology August 2014)

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group (The Lancet, Sept 2013)   

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group (The Lancet, Sept 2013) 

Guidelines on management of low-grade gliomas: report of an EFNS–EANO Task Force (European Journal of Neurology August 2010)

Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors (Neurology May 2000)

Response Assessment


Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative (Lancet Oncology, March 2018)

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (Neuro-oncology April 2017)

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas (Neuro-oncology April 2016)

Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group (The Lancet Oncology, December 2015)

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas (The Lancet Oncology, June 2011)

Updated: March 2018